Home | Welcome to Contract Pharma   
Last Updated Wednesday, April 16 2014
Print

Cangene Acquisition Gets Ontario Court Approval



By Kristin Brooks



Published February 19, 2014
Cangene Corp. received approval from the Ontario Superior Court of Justice for the previously announced acquisition of Cangene by Emergent BioSolutions, Inc. Under the court-approved Plan of Arrangement, Cangene shareholders will receive $3.24 per share in cash, for an aggregate purchase price of $222 million.
 
The transaction, subject to additional customary closing conditions, is expected to close in February 2014.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On